
Oncology NEWS International
- Oncology NEWS International Vol 4 No 7
- Volume 4
- Issue 7
Interleukin-11 to Enter Phase III
CAMBRIDGE, Mass--In a phase II study, Genetics Institute's recombinant human interleukin-11 (rhIL-11) restored platelets in throm-bocytopenic patients undergoing cancer chemotherapy to the extent that significantly fewer rhIL-11 treated patients required platelet transfusions, compared to placebo.
CAMBRIDGE, Mass--In a phase II study, Genetics Institute's recombinanthuman interleukin-11 (rhIL-11) restored platelets in throm-bocytopenicpatients undergoing cancer chemotherapy to the extent that significantlyfewer rhIL-11 treated patients required platelet transfusions,compared to placebo.
Based on this favorable outcome, the company plans to begin aphase III study by the end of this year.
Articles in this issue
almost 31 years ago
ODAC Recommends Accelerated FDA Approval of Ethyol for Cytoprotectionalmost 31 years ago
House Panel Holds Hearing on Self-Referralalmost 31 years ago
Health-Related Legislationalmost 31 years ago
Mitoguazone Appears Promising in HIV-Associated Refractory NHLalmost 31 years ago
Responses to Anti-HER2 MoAb Seenalmost 31 years ago
NCI Committed to Increasing Minority Participation in Clinical Trialsalmost 31 years ago
MoAb May Improve Detection of Colon And Rectal Canceralmost 31 years ago
Zeneca Files NDA for Arimidexalmost 31 years ago
Cord Blood is Used as Source of Stem Cells for Pediatric TransplantationRelated Content


TIP113 HERTHENA-PanTumor01 (NCT06172478): Expansion of a Global Phase 2 Trial of HER3-DXd in Patients With Advanced/Metastatic HR+/HER2− Breast Cancer




















































